|
gptkbp:instanceOf
|
gptkb:drug
disease-modifying antirheumatic drug
|
|
gptkbp:administeredBy
|
injection
infusion
|
|
gptkbp:alternativeTo
|
gptkb:conventional_synthetic_DMARDs
|
|
gptkbp:approvedBy
|
gptkb:FDA
late 1990s
|
|
gptkbp:category
|
monoclonal antibodies
recombinant proteins
fusion proteins
|
|
gptkbp:combines
|
gptkb:methotrexate
|
|
gptkbp:compatibleWith
|
osteoarthritis
gout
|
|
gptkbp:contraindication
|
active infection
latent tuberculosis (untreated)
|
|
gptkbp:cost
|
high
|
|
gptkbp:example
|
gptkb:rituximab
gptkb:ustekinumab
gptkb:tocilizumab
gptkb:etanercept
gptkb:golimumab
gptkb:infliximab
gptkb:abatacept
gptkb:certolizumab_pegol
gptkb:adalimumab
gptkb:secukinumab
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
biologic DMARDs
|
|
gptkbp:mechanismOfAction
|
target specific components of the immune system
|
|
gptkbp:monitors
|
regular blood tests
screening for infections
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
allergic reactions
injection site reactions
increased risk of infection
malignancy (rare)
|
|
gptkbp:storage
|
refrigeration required
|
|
gptkbp:target
|
gptkb:interleukin-6
gptkb:B_cells
gptkb:T_cells
gptkb:tumor_necrosis_factor_alpha
|
|
gptkbp:usedFor
|
gptkb:juvenile_idiopathic_arthritis
gptkb:systemic_lupus_erythematosus
gptkb:psoriatic_arthritis
rheumatoid arthritis
ankylosing spondylitis
|
|
gptkbp:bfsParent
|
gptkb:DMARDs
|
|
gptkbp:bfsLayer
|
7
|